Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C.

Castera L, Constant A, Henry C, Champbenoit P, Bernard PH, De Ledinghen V, Demotes-Mainard J, Couzigou P.

Aliment Pharmacol Ther. 2006 Oct 15;24(8):1223-30.

2.

Efficacy and safety of peginterferon plus ribavirin for patients aged ≥ 65 years with chronic hepatitis C: a systematic review and meta-analysis.

Yang Z, Zhuang L, Yang L, Liu C, Lu Y, Xu Q, Chen X, Chen L.

Clin Res Hepatol Gastroenterol. 2014 Sep;38(4):440-50. doi: 10.1016/j.clinre.2013.08.013. Epub 2013 Oct 28. Review.

PMID:
24176812
3.

Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients.

Crespo M, Sauleda S, Esteban JI, Juarez A, Ribera E, Andreu AL, Falco V, Quer J, Ocaña I, Ruiz I, Buti M, Pahissa A, Esteban R, Guardia J.

J Viral Hepat. 2007 Apr;14(4):228-38.

PMID:
17381714
4.

Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.

Parise E, Cheinquer H, Crespo D, Meirelles A, Martinelli A, Sette H, Gallizi J, Silva R, Lacet C, Correa E, Cotrim H, Fonseca J, Paraná R, Spinelli V, Amorim W, Tatsch F, Pessoa M; Brazilian Pegasys Cooperative Study Group.

Braz J Infect Dis. 2006 Feb;10(1):11-6. Epub 2006 Jun 2.

5.

De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C.

Martín-Santos R, Díez-Quevedo C, Castellví P, Navinés R, Miquel M, Masnou H, Soler A, Ardevol M, García F, Galeras JA, Planas R, Solà R.

Aliment Pharmacol Ther. 2008 Feb 1;27(3):257-65. Epub 2007 Nov 6.

6.

[Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea].

Lee H, Choi MS, Paik SW, Kim JH, Kim DY, Lee JH, Koh KC, Yoo BC, Rhee JC, Song SM.

Korean J Hepatol. 2006 Mar;12(1):31-40. Korean.

7.
8.

Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.

Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, Cheinquer H, Craxi A, Cooksley G, Klaskala W, Pettit K, Patel KK, Green J.

Am J Gastroenterol. 2004 Aug;99(8):1490-6.

PMID:
15307866
9.

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.

Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, Chiu CF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL.

Gut. 2007 Apr;56(4):553-9. Epub 2006 Sep 6.

10.

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK; International Hepatitis Interventional Therapy Group.

Gastroenterology. 2002 Oct;123(4):1061-9.

PMID:
12360468
11.

Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.

Abergel A, Hezode C, Leroy V, Barange K, Bronowicki JP, Tran A, Alric L, Castera L, Bernard PH, Henquell C, Lafeuille H, Ughetto S, Darcha C, Chevallier M, Martineau N, Dubost S, Randl K, Dhumeaux D, Bommelaer G, Bonny C; French multicenter study group.

J Viral Hepat. 2006 Dec;13(12):811-20.

PMID:
17109680
12.
13.

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group.

Ann Intern Med. 2004 Mar 2;140(5):346-55.

PMID:
14996676
14.

Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.

Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, Hwang SJ, Chang WY, Chang TT, Hsieh TY, Liu CJ, Chen DS.

J Viral Hepat. 2005 May;12(3):283-91.

PMID:
15850469
15.

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.

PMID:
18081356
16.
17.

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.

Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE; Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group.

Gastroenterology. 2004 Apr;126(4):1015-23; discussion 947.

PMID:
15057741
18.

Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.

Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT.

Int J Artif Organs. 2008 Apr;31(4):295-302.

PMID:
18432584
19.

Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.

Schaefer M, Hinzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, Sarkar R, Friebe A, Heinz A, Kluschke M, Ziemer M, Gutsche J, Weich V, Halangk J, Berg T.

Hepatology. 2007 Oct;46(4):991-8.

PMID:
17668880
20.

Safety of peginterferon in the treatment of chronic hepatitis C.

Hashemi N, Rossi S, Navarro VJ, Herrine SK.

Expert Opin Drug Saf. 2008 Nov;7(6):771-81. doi: 10.1517/14740330802423291 . Review.

PMID:
18983223

Supplemental Content

Support Center